LOUISVILLE, Colo. — December 18, 2025 — Leads & Copy —
Charlotte’s Web Holdings, Inc. will participate as a CBD provider supporting senior oncology patient treatment under the Center for Medicare and Medicaid Innovation’s (CMMI) newly announced pilot program.
The program will give seniors living with cancer access to science-backed CBD products with Medicare and Medicaid reimbursement, creating a new model of care prioritizing personalization, accessibility, and affordability.
Charlotte’s Web will offer a set of products to address oncology patient needs early in 2026 through a secure online healthcare portal. The platform combines eCommerce with advanced data security to protect patient and physician information and is a continuing expansion to the Company’s established medical channel business. This initiative introduces long-awaited optionality, with room for future product expansion.
According to the company, this initiative represents a transformative moment in senior healthcare policy, introducing long-awaited flexibility and optionality for patients and providers seeking therapeutic hemp products.
“Charlotte’s Web is proud to participate in the CMMI program to bring trusted CBD options to underserved seniors battling cancer,” said CEO Bill Morachnick. “Charlotte’s Web was founded to help Charlotte Figi, whose medically challenging life became a CBD success story. Her journey inspired research, opened doors to access, and changed perceptions about the therapeutic benefits of CBD around the globe.
Morachnick added that the Company made a promise to Charlotte, her mother Paige, and the millions who followed her: to set the standard for the entire industry by leading with quality, consistency, and science. He said that as the CBD market leader and a trusted partner throughout the country among healthcare practitioners, this initiative marks a historic step forward, uniquely positioning Charlotte’s Web to expand access to safe, non-intoxicating hemp CBD products through existing pathways. He also thanked the administration, CMMI, and all key stakeholders for their vision and persistence in making this possible.
The company said affordability is central to this initiative. There are 67 million Medicare beneficiaries nationwide, and nearly 20% of seniors use CBD for pain, arthritis, and other age-related conditions. Charlotte’s Web believes that this pilot program addresses a critical gap in senior supportive care by reducing out-of-pocket costs through Medicare reimbursement, making CBD more affordable for seniors and low-income Americans while lowering downstream healthcare expenses.
Charlotte’s Web Scientific Advisory Board (SAB) will play a critical role in guiding its program, ensuring it reflects the Company’s commitment to scientific rigor, clinical validation, and ethical responsibility. Comprised of interdisciplinary experts, the SAB advises on product integrity, patient and provider education, and long-term innovation strategies.
“Scientific rigor underpins every aspect of this program. With more than a decade of consumer use and extensive safety studies, Charlotte’s Web integrates real-world evidence, patient-reported outcomes, and clinical insights into its R&D process to ensure products are safe and effective,” said Dr. Marcel Bonn-Miller, Chief Scientific Officer at Charlotte’s Web.
Realm of Caring, a leading 501(c)(3) nonprofit, provides support and research coordination for patients and healthcare providers for this program. Through this program, Realm of Caring will provide cannabinoid therapy guidance through evidence-based, cannabinoid education for individuals and their healthcare providers while capturing real-world data and lived experiences to inform program evolution and future research. Founded in 2013 with a legacy in research leadership, Realm of Caring has published multiple peer-reviewed studies validating CBD’s effects for sleep, anxiety, depression, and quality of life, while reducing hospital visits.
Under the Medicare pilot framework, enrolled patients will be connected with Realm of Caring’s support services as part of their program participation. This includes personalized consultations on product selection and dosing, ongoing communication with healthcare providers, and structured outcomes tracking, ensuring that participants receive comprehensive care coordination rather than product access alone. This integrated support model reflects the program’s commitment to evidence-based, patient-centered CBD healthcare delivery.
“This initiative represents a blueprint for patient-centered CBD healthcare – one that advances alongside our medical channel expansion and deepening clinical research. The potential of the hemp plant is still being furthered, and studies like the Phase 2 FDA clinical trials investigating hemp-based therapies for autism spectrum disorder at our affiliated company, DeFloria, are critical to making its therapeutic promise even more accessible for health insurance-covered care. Our work through this program and our ongoing research demonstrate how rigorous science and compassionate care can converge to serve patients who need it most,” stated Mr. Morachnick.
Charlotte’s Web Holdings, Inc., headquartered in Louisville, Colorado, is a botanical wellness innovation company and market leader in hemp extract wellness. The Company’s product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery), CBN gummies, CBG gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte’s Web maintains stringent control over product quality and consistency with analytic testing for quality assurance. Charlotte’s Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online through the Company’s website.
Bill Morachnick, CEO
Dr. Marcel Bonn-Miller, Chief Scientific Officer
Source: Charlotte’s Web Holdings, Inc.
